Scholar Rock Holding Corp
$ 44.18
-1.14%
12 Jun - close price
- Market Cap 5,294,016,000 USD
- Current Price $ 44.18
- High / Low $ 46.41 / 44.09
- Stock P/E N/A
- Book Value 2.32
- EPS -3.45
- Next Earning Report 2026-08-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.54 %
- ROE -1.39 %
- 52 Week High 52.19
- 52 Week Low 27.07
About
Scholar Rock Holding Corporation, a clinical-phase biopharmaceutical company, is focused on the discovery and development of drugs for the treatment of serious diseases in which protein growth factor signaling plays a critical role. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$59.31
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-03-03 | 2025-11-14 | 2025-08-06 | 2025-05-14 | 2025-02-27 | 2024-11-12 | 2024-08-08 | 2024-05-07 | 2024-03-19 | 2023-11-07 | 2023-08-09 |
| Reported EPS | -0.83 | -0.88 | -0.9 | -0.98 | -0.67 | -0.61 | -0.66 | -0.6 | -0.59 | -0.5 | -0.53 | -0.47 |
| Estimated EPS | -0.78 | -0.8983 | -0.84 | -0.67 | -0.71 | -0.6288 | -0.6 | -0.59 | -0.51 | -0.49 | -0.51 | -0.55 |
| Surprise | -0.05 | 0.0183 | -0.06 | -0.31 | 0.04 | 0.0188 | -0.06 | -0.01 | -0.08 | -0.01 | -0.02 | 0.08 |
| Surprise Percentage | -6.4103% | 2.0372% | -7.1429% | -46.2687% | 5.6338% | 2.9898% | -10% | -1.6949% | -15.6863% | -2.0408% | -3.9216% | 14.5455% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-05 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.84 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SRRK
2026-06-13 11:09:00
Scholar Rock announced it granted inducement equity awards covering 134,345 shares to eleven new employees under Nasdaq Listing Rule 5635(c)(4). These awards include stock options and restricted stock units, subject to vesting schedules and the company's 2022 Inducement Equity Plan. The grants are a material inducement for individuals to join Scholar Rock and are consistent with Nasdaq rules for new hires.
2026-06-09 15:09:35
Scholar Rock Holding Corporation presented at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, at 10:00 AM EDT. The transcript indicates a presentation by David Hallal from Scholar Rock. The full article content is reserved for subscribers.
2026-06-09 14:10:48
This page provides a detailed look at Scholar Rock Holding Corp (SRRK)'s financial data over 30 years, offering key metrics such as market cap, enterprise value, PE ratio, PB ratio, and GF Score. It also includes growth rates for revenue, EPS, EBIT, EBITDA, free cash flow, dividends, book value, and price performance. The content is presented by GuruFocus, a financial analysis platform.
2026-06-08 21:09:35
Scholar Rock Holding Corp. director Michael Gilman has been awarded 6,839 Restricted Stock Units (RSUs) and options to purchase 4,310 shares of common stock at an exercise price of $45.33 per share. These awards will vest based on continued service to the company, with the RSUs vesting by June 15, 2027, or the next Annual Meeting, and the options vesting one year post-grant or at the next Annual Meeting and expiring in 2036. Following these transactions, Gilman's direct holdings include 62,055 common shares (comprising 55,216 shares and 6,839 RSUs) and 4,310 stock options.
2026-06-08 21:09:35
Jeffrey S. Flier, a director at Scholar Rock Holding Corp (SRRK), was granted 6,839 Restricted Stock Units (RSUs) and 4,310 stock options with an exercise price of $45.33 per share. These equity awards are part of his compensation, designed to align his interests with the company's long-term performance and continued service. The RSUs and options include specific vesting schedules tied to continued service or the company's next Annual Meeting.
2026-06-08 20:41:12
Scholar Rock Holding Corp (SRRK) director Joshua Reed received equity compensation, including 6,839 Restricted Stock Units (RSUs) and options for 4,310 shares at an exercise price of $45.33 per share. These grants are part of his routine compensation package, with vesting conditional on continued service. Following these transactions, Reed's total holdings include 22,571 common shares and RSUs, plus the 4,310 stock options.
